Scinai Immunotherapeutics Ltd. (SCNI) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $0.52 (-2.92% 1D, market cap $1.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SCNI ranks #894 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCNI carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, CLDI (Calidi Biotherapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and PMCB (PharmaCyte Biotech Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -30.2%, cap $3.6M). Among the 5-stock peer group, SCNI leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
Per SCNI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611747), Scinai Immunotherapeutics Ltd. generated $1.3M in revenue (+99.2% YoY), -$8.3M in net income, and -$6.1M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SCNI currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.48) and Max Pain ($0.55) forces dealer call-delta covering toward $16.28.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Scinai Immunotherapeutics Ltd. (SCNI) dropped -2.92% to $0.52, trading at 2% of its 52-week range ($0.47 – $15.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics (NASDAQ:AARD) stock
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) today issued the following letter to shareholders from Chief Executive Officer Amir Reichman.
Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their outstanding shares is
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +99.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SCNI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SCNI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Scinai Immunotherapeutics Ltd. (SCNI) ranks #894 by composite RQD confidence (29/100, grade E) and #1011 by equity capitalization ($1.4M). Within this direct 5-issuer industry benchmark cohort, SCNI leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. PMCB currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with SCNI at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SCNI
ACTIVE
Scinai Immunotherapeutics Ltd. | E | 29/100 | — | -30.0% | -35.0% | -2.92% | $1.4M | Benchmark Subject |
| CLDI Calidi Biotherapeutics Inc. | E | 31/100 | — | — | -35.0% | -4.29% | $2.5M | /cldi-vs-scni → |
| PMCB PharmaCyte Biotech Inc. | D- | 35/100 | — | — | -30.2% | -0.78% | $3.6M | /pmcb-vs-scni → |
| CRIS Curis Inc. | E | 27/100 | — | — | -35.0% | +20.82% | $3.7M | /cris-vs-scni → |
| LIMN Liminatus Pharma Inc. (Class A) | E | 34/100 | — | — | -35.0% | -0.86% | $3.9M | /limn-vs-scni → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scinai Immunotherapeutics Ltd. (SCNI) reported GAAP revenue of $1.3M (+99.2% vs. FY2024 revenue of $658.0K ) , GAAP net income of -$8.3M, operating cash flow of -$6.0M, and free cash flow of -$6.1M (+4.6% YoY). On the balance sheet, SCNI closed FY2025 with $11.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.3M | -$8.3M | -$6.0M | -$6.1M | $11.6M | — |
| FY2024 (FY) | 2024-12-31 | $658.0K | $4.8M | -$6.3M | -$6.3M | $13.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$6.5M | -$9.4M | -$9.4M | — | — |
As of 2026-11-02, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $0.52 (-2.92% 1D, market cap $1.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SCNI ranks #894 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCNI carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, CLDI (Calidi Biotherapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and PMCB (PharmaCyte Biotech Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -30.2%, cap $3.6M). Among the 5-stock peer group, SCNI leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
Per SCNI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611747), Scinai Immunotherapeutics Ltd. generated $1.3M in revenue (+99.2% YoY), -$8.3M in net income, and -$6.1M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SCNI last traded at $0.52 (-2.92% on volume of 46,013 shares), positioning the stock -64.86% below its 50-day simple moving average ($1.48) and -88.24% below its 200-day simple moving average ($4.42). Across its 52-week range of $0.47 to $15.50, SCNI sits at the 0.3% percentile with a 14-day RSI of 26.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.59).
Why SCNI Stock dropped -2.92% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).